Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual Meeting

Rhea-AI Summary

Kintara Therapeutics, Inc. (Nasdaq: KTRA), a biopharmaceutical company, announced acceptance of three posters for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting from November 16-20 in Tampa, Florida. The studies focus on VAL-083's application in various cancers, including a Phase 2 study in glioblastoma multiforme (GBM) and reports on recurrent ependymoma and glioblastoma treatments. Kintara’s VAL-083 and REM-001 therapies aim to address unmet medical needs in cancer treatment.

Positive

• Acceptance of three abstracts for presentation at the SNO Annual Meeting can enhance visibility and credibility in the oncology community.
• Kintara is advancing VAL-083 and REM-001 towards late-stage pivotal testing, indicating progress in their drug development pipeline.
• VAL-083 has demonstrated clinical activity against various cancers, supporting its potential market value.

Negative

• None.

SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.(Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that three posters have been accepted for data presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting. The 2022 SNO Annual Meeting will be held from November 16 through November 20, 2022 in Tampa, Florida.

Data Presentations:

Phase 2 Study of VAL-083 and Radiotherapy in Newly-Diagnosed, MGMT-unmethylated GBM
Poster Presenter: Zhongping Chen, MD, Ph.D. – Sun Yat-sen University Cancer Center
(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)

Recurrent RELA Fusion-Positive Ependymoma Treated with VAL-083 under Expanded Access: A Case Report
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)

VAL-083 in Patients with Recurrent Glioblastoma Treated under Expanded Access Program
Poster Presenter: Carlos Kamiya-Matsuoka, MD – MD Anderson Cancer Center
(Presentation Time: Friday, November 18, 2022 - 7:30 to 9:30 pm ET)

ABOUT KINTARA

Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for Glioblastoma Multiforme (GBM) and REM-001 for Cutaneous Metastatic Breast Cancer (CMBC).

VAL-083 is a "first-in-class," small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g., NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently advancing VAL-083 in the GBM AGILE study to support the development and commercialization of VAL-083 in GBM.

Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications. REM-001 therapy has been previously studied in four Phase 2/3 clinical trials in patients with CMBC who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions, and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late-stage pivotal testing.

For more information, please visit www.kintara.com or follow us on Twitter at @Kintara_Thera, Facebook and LinkedIn.

SAFE HARBOR STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including statements regarding the status of the Company's clinical trials and the GBM AGILE study. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the impact of the COVID-19 pandemic on the Company's operations and clinical trials; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended June 30, 2021, the Company's Quarterly Reports on Form 10-Q, and the Company's Current Reports on Form 8-K.

CONTACT: ir@kintara.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kintara-therapeutics-announces-three-abstracts-have-been-accepted-for-the-2022-society-for-neuro-oncology-annual-meeting-301620008.html

SOURCE Kintara Therapeutics

FAQ

What is the significance of Kintara Therapeutics presenting at the 2022 SNO Annual Meeting?

Kintara's acceptance of three posters at the SNO Annual Meeting highlights its research advancements and may lead to increased visibility and collaborations in the oncology sector.

What studies will Kintara Therapeutics present at the SNO Annual Meeting?

Kintara will present data on VAL-083's use in a Phase 2 study for newly-diagnosed GBM and case reports on recurrent ependymoma and glioblastoma.

When is the SNO Annual Meeting where Kintara will present?

The SNO Annual Meeting will take place from November 16 to November 20, 2022.

What is VAL-083 and its relevance to Kintara's drug development?

VAL-083 is a first-in-class chemotherapeutic agent being developed by Kintara for treating multiple cancers, including GBM, with a promising mechanism of action.

What is the current status of Kintara’s REM-001 program?

Kintara is advancing REM-001, a therapy for Cutaneous Metastatic Breast Cancer (CMBC), into late-stage pivotal testing after showing an 80% complete response rate in past clinical trials.